Kardigan names Kristin Reinke to board, Giordano departs
The cardiovascular-focused biotech added a Google finance executive to chair its Audit Committee as a founding director stepped down.
SEC filing
Latest
3 stories
Yesterday
Tuesday, August 18
Kardigan registers Phase 3 open-label extension for danicamtiv in genetic DCM
Tuesday, August 11
Kardigan advances three late-stage cardiovascular trials, reports $660.7M cash
The company started Phase 3 enrollment for danicamtiv in DCM and reported cash of $660.7 million as of June 30, 2026, following its June IPO.
SEC filing